Whalerock Point Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Whalerock Point Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-84,900	Closed	-$367K	–	150
2015 Q1	$367K	Buy	84,900 +52,500	+162%	+$189K	0.15%	106
2014 Q4	$96K	Buy	32,400 +2,000	+7%	+$5.49K	0.04%	142
2014 Q3	$100K	Buy	+30,400	New	+$79.4K	0.05%	146

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Whalerock Point Partners's CPRX Position: Q2 2015 in Review

Whalerock Point Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2015, closing a stake of 84,900 shares — an estimated $367K sold.

Whalerock Point Partners first reported a position in CPRX in Q3 2014 and held it in 3 quarters. The position peaked at $367K in Q1 2015. 87 funds tracked by Wall St. Rank hold CPRX as of Q2 2015.

Whalerock Point Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2015 after selling out during the quarter.
Whalerock Point Partners sold 84,900 Catalyst Pharmaceutical shares in Q2 2015, an estimated $367K.
Whalerock Point Partners first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 3 quarters.
Whalerock Point Partners's Catalyst Pharmaceutical position peaked at $367K in Q1 2015.
87 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2015.

Based on Whalerock Point Partners's 13F filing for Q2 2015, filed 28 Jul 2015.